JMP Securities Reiterates Market Outperform on Marinus Pharma, Maintains $18 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason West reiterated a Market Outperform rating on Marinus Pharma (NASDAQ:MRNS) and maintained an $18 price target.
May 30, 2023 | 12:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jason West reiterated a Market Outperform rating on Marinus Pharma and maintained an $18 price target.
The reiteration of the Market Outperform rating and maintenance of the $18 price target by JMP Securities analyst Jason West indicates a positive outlook for Marinus Pharma's stock in the short term. This news is directly related to MRNS and is important for investors as it reflects the analyst's confidence in the company's performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100